Clinical and Translational Science (Jul 2022)

Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis

  • Chalirmporn Atasilp,
  • Mohitosh Biswas,
  • Pimonpan Jinda,
  • Nutthan Nuntharadthanaphong,
  • Jiratha Rachanakul,
  • Yaowaluck Hongkaew,
  • Natchaya Vanwong,
  • Surasak Saokaew,
  • Chonlaphat Sukasem

DOI
https://doi.org/10.1111/cts.13277
Journal volume & issue
Vol. 15, no. 7
pp. 1613 – 1633

Abstract

Read online

Abstract Effects of UGT1A1*6 and UGT1A1*28 genetic polymorphisms on irinotecan‐induced severe toxicities in Asian cancer patients are inconclusive. Also, ABCC2 c.3972C>T may affect toxicity of irinotecan. The aim was to assess the aggregated risk of neutropenia or diarrhea in Asian cancer patients taking irinotecan and inherited UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic variants. A PubMed literature search for eligible studies was conducted. Odds ratios (ORs) were measured using RevMan software where p values T genetic variant were not significantly associated with neutropenia (OR 1.67; 95% CI 0.98–2.84; p = 0.06) and were significantly associated with a reduction in irinotecan‐induced diarrhea (OR 0.31; 95% CI 0.11–0.81; p = 0.02). Asian cancer patients should undergo screening for both UGT1A1*6 and UGT1A1*28 genetic variants to reduce substantially irinotecan‐induced severe toxicities.